The European Commission has expanded the scope of Novartis’ Zykadia to include the first line treatment of patients with non-small cell lung cancer (NSCLC) whose tumours are anaplastic lymphoma kinase (ALK)-positive.
Read More
US regulators have green-lighted the use of Novartis Zykadia as a first-line treatment option for some patients with non-small cell lung cancer.
Read More
US regulators are undertaking a speedy review of Novartis’ application to expand the use of Zykadia to include its first-line use in patients with ALK positive non small cell lung cancer (NSCLC).
Read More
Lung cancer patients in England and Wales could soon get ‘routine’ NHS access to Novartis’ Zykadia after the National Institute for Health and Care Excellence backed its use in final draft guidelines.
Read More
